News & Updates
Filter by Specialty:
Show Multimedia Only

Dalpiciclib-pyrotinib-endocrine therapy passes trial for breast cancer
25 Aug 2025
byStephen Padilla
Treatment with dalpiciclib combined with pyrotinib and endocrine therapy exhibits antitumour activity with no new safety signals in estrogen receptor (ER)-positive HER2-positive advanced breast cancer, as shown by the results of a phase II trial.